Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine exchanges : Nasdaq save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | News | $0.7013 -17.98% -21.92% 420K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K
|
Manufacturing
|
| O: 0.25%
H: 0.0%
C: 0.0%
evx-01 first vaccine cancer trial
Pneumococcal Vaccine Market, 41% of Growth to Originate from North America, Technavio
Published: 2024-04-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
pneumococcal vaccine growth
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: -6.28%
H: 1.25%
C: -13.83%
vaccine results study platform
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: 2.79%
H: 2.03%
C: 0.34%
vaccine influenza collaboration program
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
EVAX | $4.2 -0.47% -0.48% 31K
|
Manufacturing
|
| O: 6.58%
H: 14.71%
C: 14.12%
vaccine infection results
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Published: 2024-03-27 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 2.02%
H: 1.41%
C: 0.92%
vaccine trials
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 0.0%
H: 7.38%
C: 5.74%
vaccine congress world
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Published: 2024-03-26 (Crawled : 06:00) - globenewswire.com
DVAX | $11.78 3.88% 3.74% 9.3M
|
Health Technology
|
| O: 0.72%
H: 0.4%
C: -1.75%
candidate vaccine valneva trial
Veterinary Vaccine Global Market Forecast Report: A $19.86 Billion Market by 2033, Registering 7.3% CAGR During 2023-2033
Published: 2024-03-18 (Crawled : 19:00) - prnewswire.com
ELAN | $12.95 -4.57% 0.0% 5.7M
|
Process Industries
|
| O: -0.63%
H: 0.92%
C: 0.0%
PAHC | $13.31 2.07% 2.03% 130K
|
Health Technology
|
| O: -0.16%
H: 0.8%
C: -0.08%
veterinary vaccine global market
World Vaccine Market Research Report 2023-2024 and 2030 - Increasing Consumer Awareness Towards Immunization Fueling Growth Amid Growing Prevalence of Infectious Diseases
Published: 2024-03-12 (Crawled : 02:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
report vaccine world research growing growth market
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: -1.23%
H: 2.18%
C: 0.62%
vaccine congress world presentation
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $172.54 -19.21% 50
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Published: 2024-03-05 (Crawled : 07:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration trial
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
IMNN | $1.16 3.11% 3.02% 95K
|
Manufacturing
|
| O: 1.73%
H: 5.49%
C: 3.44%
imnn-101 vaccine preclinical
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.